Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a solution set to lower the cost of treating bladder cancer and also help hospitals save money. As a result, Imagin will create a win-win situation for every party involved. The i/Blue(TM) Imaging System, Imagin’s proprietary solution, achieves this in two ways. “By displaying the blue light image that shows the highlighted cancer cells alongside the white light image that shows the full landscape of the bladder, the i/Blue Imaging System will provide surgeons with improved visualization to locate and resect tumors. The overall result is a reduction in the cost of treatment as detailed in a report by Urology Times.” The article detailing these developments continues, “Further, the i/Blue Imaging System’s camera head can be attached to any cystoscope, meaning that a hospital need not buy new cystoscopes to use the blue light fluorescent technology.”
To view the full article, visit https://ibn.fm/eG3En
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork